01PEPTIDE
Retatrutide
GLP-1 / GIP / Glucagon triple agonist for substantial weight loss and metabolic improvement.
Weight ManagementAppetiteGlucose / Insulin
EXPLORE THIS GOAL · MW
Weight Management research
Weight Management records within Metabolic + Weight. Structured links are generated from shared research-goal tags.
01
Relevant peptides
02PEPTIDE
Tirzepatide
Dual GIP / GLP-1 receptor agonist for superior weight loss and glycemic control.
Weight ManagementAppetiteGlucose / Insulin
03PEPTIDE
Semaglutide
Long-acting selective GLP-1 receptor agonist for weight loss and glycemic control.
Weight ManagementAppetiteGlucose / Insulin
04PEPTIDE
Cagrilintide
Long-acting amylin analog for appetite regulation and weight management (often studied with semaglutide as CagriSema).
Weight ManagementAppetiteFat Loss
05PEPTIDE
Cagrilintide + Semaglutide (CagriSema)
Fixed dual combination of long-acting amylin analog + GLP-1 agonist for enhanced weight loss.
Weight ManagementAppetiteGlucose / Insulin
06PEPTIDE
AOD 9604
Modified hGH fragment (176-191) studied for lipolysis without significant IGF-1 elevation.
Fat LossWeight ManagementBody Composition
07PEPTIDE
Survodutide
An investigational GLP-1 and glucagon receptor dual agonist in clinical development for obesity and metabolic liver disease.
Weight ManagementAppetiteFat Loss
08PEPTIDE
Mazdutide
A GLP-1 and glucagon receptor dual agonist studied in obesity and type 2 diabetes, with development and regulatory status varying by region.
Weight ManagementGlucose / InsulinFat Loss
09PEPTIDE
Pemvidutide
An investigational GLP-1 and glucagon receptor dual agonist studied for obesity and metabolic liver disease.
Weight ManagementFat LossBody Composition
10PEPTIDE
Liraglutide
An approved daily GLP-1 receptor agonist studied for type 2 diabetes, weight management and cardiovascular outcomes.
Weight ManagementAppetiteGlucose / Insulin
02
Related protocols
03
Popular comparisons
04
Related research
SPONSOR UPDATETRIUMPH-1 Phase 3 topline resultsRetatrutide · Eli Lilly and Company · 2026SPONSOR UPDATETRIUMPH-2 and TRIUMPH-3 Phase 3 topline results and planned regulatory submissionRetatrutide · Eli Lilly and Company · 2026REGULATORYWhat to know about retatrutideRetatrutide · Eli Lilly and Company · 2026CLINICAL TRIALCoadministered Cagrilintide and Semaglutide in Adults with Overweight or ObesityCagrilintide + Semaglutide (CagriSema) · New England Journal of Medicine · 2025CLINICAL TRIALTriple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver diseaseRetatrutide · Nature Medicine · 2024CLINICAL TRIALGlucagon and GLP-1 receptor dual agonist survodutide for obesitySurvodutide · The Lancet Diabetes & Endocrinology · 2024
05
Tools
06
Related goals
BUILD FROM THIS RESEARCH CONTEXT
Build a stack for Weight Management
The goal stays visible in the stack builder. Related records are suggestions by tag overlap; you choose what to add.